Table 3.

Subgroups analysis of ORR and DCR.

Subgroups	Objective response rate (ORR)						Disease control rate (DCR)
	Trials	Study event rates		RR (95% CI)	I 2	p	Trials	Study event rates		RR (95% CI)	I 2	p
		Aidi plus GBC	GBC					Aidi plus GBC	GBC
Totality	50	1041/1894	735/1848	1.38 (1.29, 1.48)	0%	<0.00001	49	1604/1876	1355/1826	1.15 (1.12, 1.19)	0%	<0.00001*
Subgroups analysis via doses
Aidi injection (40 ml/times)	1	11/24	8/24	1.38 (0.67, 2.81)	NA	0.38	1	19/24	17/24	1.12 (0.80, 1.55)	NA	0.51
Aidi injection (50 ml/times)	26	478/929	359/934	1.34 (1.21, 1.48)	0%	<0.00001	25	772/911	676/912	1.14 (1.09, 1.20)	0%	<0.00001*
Aidi injection (60 ml/times)	7	180/321	123/302	1.36 (1.16, 1.61)	0%	0.0002	7	269/321	214/302	1.18 (1.08, 1.29)	0%	0.0002*
Aidi injection (80 ml/times)	5	100/170	63/163	1.52 (1.20, 1.92)	24%	0.004	5	147/170	114/163	1.23 (1.10, 1.38)	0%	0.0003*
Aidi injection (50–150 ml/times)	11	272/450	182/425	1.42 (1.25, 1.62)	0%	<0.00001	11	397/450	334/425	1.12 (1.06, 1.19)	0%	<0.0001*
Subgroups analysis via treatment time
10–30 days	27	517/996	389/964	1.28 (1.16, 1.41)	0%	<0.00001	26	838/984	704/948	1.15 (1.10, 1.20)	0%	<0.00001*
31–60 days	18	422/699	284/687	1.46 (1.31, 1.63)	0%	<0.00001	19	622/734	532/719	1.14 (1.09, 1.21)	0%	0.0002*
>60 days	5	102/199	62/197	1.63 (1.28, 2.08)	0%	<0.0001	4	144/158	119/159	1.22 (1.10, 1.35)	0%	<0.00001*

Note: Aidi: Aidi injection; GBC: gemcitabine-based chemotherapy; RR, relative ratio; CI: confidence interval.

*Favours Aidi plus GBC group with statistical significance.